Join

Compare · NMTC vs WST

NMTC vs WST

Side-by-side comparison of NeuroOne Medical Technologies Corporation (NMTC) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NMTC and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • WST is the larger of the two at $29.12B, about 922.4x NMTC ($31.6M).
  • Over the past year, NMTC is up 26.0% and WST is up 41.7% - WST leads by 15.6 points.
  • NMTC has been more active in the news (6 items in the past 4 weeks vs 4 for WST).
  • WST has more recent analyst coverage (15 ratings vs 4 for NMTC).
PerformanceNMTC+26.03%WST+41.67%
2025-04-28+0.00%2026-04-24
MetricNMTCWST
Company
NeuroOne Medical Technologies Corporation
West Pharmaceutical Services Inc.
Price
$4.75-0.52%
$306.12-1.10%
Market cap
$31.6M
$29.12B
1M return
+2.68%
+23.98%
1Y return
+26.03%
+41.67%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NASDAQ
NYSE
IPO
News (4w)
6
4
Recent ratings
4
15
NMTC

NeuroOne Medical Technologies Corporation

NeuroOne Medical Technologies Corporation operates as a medical technology company. It focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and other related brain related disorders. NeuroOne Medical Technologies Corporation has a strategic partnership with RBC Medical Innovations to develop and manufacture a radiofrequency generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.

WST

West Pharmaceutical Services Inc.

West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

Latest NMTC

Latest WST